SCHEDULE 13G/A: Jennison Associates Files Amended Schedule 13G for Phathom Pharmaceuticals, Reporting Zero Beneficial Ownership

Jennison Associates LLC has filed an amended Schedule 13G for Phathom Pharmaceuticals Inc., indicating a 0% beneficial ownership of the company's common stock as of April 30, 2025.

Summary

• The document is an Amendment No. 2 to a Schedule 13G filing concerning PHATHOM PHARMACEUTICALS INC Common Stock.
• The reporting entity is Jennison Associates LLC, an investment adviser based in New York, NY.
• As of April 30, 2025, Jennison Associates LLC reports 0% beneficial ownership of Phathom Pharmaceuticals Inc. common stock.
• This 0% ownership includes no shares with sole voting power, shared voting power, sole dispositive power, or shared dispositive power.
• Jennison Associates LLC certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (Schedule 13G) reporting beneficial ownership, specifically indicating 0% ownership by Jennison Associates LLC. It contains no positive or negative operational or financial news about the issuer, Phathom Pharmaceuticals Inc.

Future Outlook

NA

Industry Context

This filing is a routine regulatory disclosure of institutional ownership, providing transparency on the beneficial ownership stake (or lack thereof) of a specific investment adviser in a publicly traded pharmaceutical company. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: Provides transparency regarding institutional ownership, specifically that Jennison Associates LLC does not hold a reportable beneficial ownership stake in Phathom Pharmaceuticals Inc.

Key Dates

Keywords

PHATHOM PHARMACEUTICALS INC, Jennison Associates LLC, Schedule 13G, Common Stock, Beneficial Ownership, Investment Adviser, SEC Filing, 71722W107